CytomX Therapeutics, Inc. financial data

Symbol
CTMX on Nasdaq
Industry
Pharmaceutical Preparations
Location
151 Oyster Point Blvd., Suite 400, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 110 % -16.5%
Debt-to-equity -795 % -89%
Return On Equity -147 % -17542%
Return On Assets 21.1 %
Operating Margin 18.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80.1M shares +18.3%
Common Stock, Shares, Outstanding 80.1M shares +19%
Entity Public Float 94.4M USD -17.3%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 84.4M shares +14.4%
Weighted Average Number of Shares Outstanding, Diluted 84.7M shares +14.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 138M USD +36.4%
Revenue from Contract with Customer, Excluding Assessed Tax 138M USD +36.4%
Research and Development Expense 83.4M USD +7.34%
General and Administrative Expense 29.7M USD -0.97%
Operating Income (Loss) 25M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 32.1M USD +866%
Income Tax Expense (Benefit) 224K USD -94.2%
Net Income (Loss) Attributable to Parent 31.9M USD +2155%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.1M USD +122%
Cash, Cash Equivalents, and Short-term Investments 102M USD -41.9%
Accounts Receivable, after Allowance for Credit Loss, Current 3.1M USD -9.59%
Assets, Current 107M USD -41.3%
Property, Plant and Equipment, Net 2.47M USD -37.7%
Operating Lease, Right-of-Use Asset 8.14M USD -33.4%
Goodwill 949K USD 0%
Other Assets, Noncurrent 66K USD -20.5%
Assets 121M USD -40.3%
Accounts Payable, Current 1.09M USD -25.4%
Employee-related Liabilities, Current 2.58M USD -68.4%
Accrued Liabilities, Current 12.3M USD -29.9%
Contract with Customer, Liability, Current 67.2M USD -49.2%
Liabilities, Current 85.8M USD -45%
Contract with Customer, Liability, Noncurrent 26.9M USD -66.4%
Operating Lease, Liability, Noncurrent 4.24M USD -54.8%
Other Liabilities, Noncurrent 4.12M USD +5.7%
Liabilities 121M USD -51.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 27K USD -71.6%
Retained Earnings (Accumulated Deficit) -692M USD +4.41%
Stockholders' Equity Attributable to Parent -456K USD +99%
Liabilities and Equity 121M USD -40.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26M USD -379%
Net Cash Provided by (Used in) Financing Activities 174K USD
Net Cash Provided by (Used in) Investing Activities 44.9M USD
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 80.1M shares +19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 162M USD -7.61%
Deferred Tax Assets, Gross 164M USD -8.16%
Operating Lease, Liability 9.39M USD -32.8%
Payments to Acquire Property, Plant, and Equipment 115K USD +140%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 31.8M USD +1796%
Lessee, Operating Lease, Liability, to be Paid 10.1M USD -35.5%
Property, Plant and Equipment, Gross 18.7M USD +0.28%
Operating Lease, Liability, Current 5.15M USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.39M USD -23.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.73M USD +2.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 731K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.39M USD -23.4%
Deferred Tax Assets, Operating Loss Carryforwards 62.5M USD +10.2%
Unrecognized Tax Benefits 20M USD +3.18%
Additional Paid in Capital 691M USD +2.25%
Amortization of Intangible Assets 36K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 2.11M USD -37.3%